Xerium Technologies (XRM) Shareholder American Securities Has Lowered Position; Clovis Oncology (CLVS) Shares Declined While Partner Fund Management LP Has Lowered Position by $12.27 Million

February 15, 2018 - By wolcottdaily

American Securities Llc decreased its stake in Xerium Technologies Inc (XRM) by 35.52% based on its latest 2017Q3 regulatory filing with the SEC. American Securities Llc sold 768,769 shares as the company’s stock rose 32.64% with the market. The institutional investor held 1.40M shares of the basic industries company at the end of 2017Q3, valued at $6.67M, down from 2.16 million at the end of the previous reported quarter. American Securities Llc who had been investing in Xerium Technologies Inc for a number of months, seems to be less bullish one the $88.55 million market cap company. The stock increased 0.19% or $0.01 during the last trading session, reaching $5.41. About 16,922 shares traded. Xerium Technologies, Inc. (NYSE:XRM) has risen 21.00% since February 15, 2017 and is uptrending. It has outperformed by 4.30% the S&P500.

Christopher Medlock James decreased its stake in Clovis Oncology Inc (CLVS) by 40.43% based on its latest 2017Q3 regulatory filing with the SEC. Partner Fund Management Lp sold 149,654 shares as the company’s stock declined 20.61% while stock markets rallied. The hedge fund run by Christopher Medlock James held 220,487 shares of the health care company at the end of 2017Q3, valued at $18.17 million, down from 370,141 at the end of the previous reported quarter. Partner Fund Management Lp who had been investing in Clovis Oncology Inc for a number of months, seems to be less bullish one the $2.63B market cap company. The stock decreased 0.76% or $0.41 during the last trading session, reaching $53.68. About 27,176 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has risen 282.71% since February 15, 2017 and is uptrending. It has outperformed by 266.01% the S&P500.

Since September 1, 2017, it had 0 insider buys, and 1 insider sale for $24,160 activity.

Investors sentiment increased to 1.21 in 2017 Q3. Its up 0.40, from 0.81 in 2017Q2. It increased, as 3 investors sold XRM shares while 16 reduced holdings. 12 funds opened positions while 11 raised stakes. 10.10 million shares or 3.33% less from 10.45 million shares in 2017Q2 were reported. The California-based Stepstone Gp Lp has invested 0.06% in Xerium Technologies, Inc. (NYSE:XRM). Travelers owns 18,606 shares. Northern Corporation reported 23,280 shares. Moreover, Redwood Capital Management Llc has 0.06% invested in Xerium Technologies, Inc. (NYSE:XRM). Buckhead Capital Management Lc reported 137,490 shares stake. 158 are owned by Evercore Wealth Management Limited Liability. Jacobs Levy Equity Mgmt has 11,678 shares. Federated Invsts Pa stated it has 3,422 shares. Howe Rusling reported 0% stake. Moreover, National Bank Of New York Mellon has 0% invested in Xerium Technologies, Inc. (NYSE:XRM) for 53,880 shares. Lsv Asset Management holds 0% or 74,000 shares in its portfolio. Moab Prtnrs Limited Com has 423,978 shares. Rutabaga Management Ltd Liability Corp Ma stated it has 0.99% in Xerium Technologies, Inc. (NYSE:XRM). Wisconsin-based Skylands Capital Ltd Com has invested 0.11% in Xerium Technologies, Inc. (NYSE:XRM). Wynnefield holds 1.97% in Xerium Technologies, Inc. (NYSE:XRM) or 1.15M shares.

Partner Fund Management Lp, which manages about $5.09B US Long portfolio, upped its stake in Salesforce Com Inc (NYSE:CRM) by 506,867 shares to 955,567 shares, valued at $89.27 million in 2017Q3, according to the filing. It also increased its holding in Box Inc by 1.64 million shares in the quarter, for a total of 2.90 million shares, and has risen its stake in Edwards Lifesciences Corp (NYSE:EW).

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 14 have Buy rating, 0 Sell and 6 Hold. Therefore 70% are positive. Clovis Oncology had 56 analyst reports since September 10, 2015 according to SRatingsIntel. The company was maintained on Monday, November 16 by Piper Jaffray. The company was initiated on Friday, August 5 by Suntrust Robinson. WallachBeth Capital downgraded it to “Hold” rating and $30 target in Tuesday, November 17 report. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Buy” rating given on Thursday, January 18 by Credit Suisse. As per Thursday, January 21, the company rating was initiated by Credit Suisse. The stock has “Hold” rating by RBC Capital Markets on Thursday, November 2. SunTrust maintained the shares of CLVS in report on Friday, September 23 with “Buy” rating. Oppenheimer maintained the shares of CLVS in report on Monday, July 31 with “Hold” rating. Leerink Swann maintained Clovis Oncology, Inc. (NASDAQ:CLVS) rating on Monday, September 18. Leerink Swann has “Buy” rating and $107.0 target. Bank of America initiated it with “Buy” rating and $74 target in Friday, January 27 report.

Investors sentiment decreased to 1.44 in Q3 2017. Its down 0.37, from 1.81 in 2017Q2. It turned negative, as 48 investors sold CLVS shares while 49 reduced holdings. 42 funds opened positions while 98 raised stakes. 47.46 million shares or 2.14% more from 46.46 million shares in 2017Q2 were reported. Columbia Wanger Asset Mngmt Ltd Llc accumulated 581,660 shares. Barclays Public Limited Liability Corp has 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 21,002 shares. Sg Americas Securities invested in 5,465 shares. Highlander Ltd Llc invested 0.02% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Gam Ag has 21,800 shares for 0.08% of their portfolio. Fmr Ltd Liability holds 1.75M shares or 0.02% of its portfolio. Healthcor LP accumulated 647,420 shares. Grp Inc invested in 29,044 shares or 0.01% of the stock. Kbc Gp Nv, a Belgium-based fund reported 40,669 shares. Creative Planning holds 64,844 shares or 0.02% of its portfolio. Moore Cap Limited Partnership accumulated 30,000 shares. Bourgeon Cap Mgmt Ltd Limited Liability Company holds 0.51% or 10,575 shares in its portfolio. Samlyn Capital Ltd Company has 522,345 shares for 1.09% of their portfolio. Sectoral Asset Mngmt, Quebec – Canada-based fund reported 251,699 shares. San Francisco Sentry Inv Grp (Ca) reported 0.01% stake.

Since August 15, 2017, it had 0 buys, and 5 selling transactions for $1.12 million activity. SPICKSCHEN THORLEF sold $292,365 worth of Clovis Oncology, Inc. (NASDAQ:CLVS) on Monday, January 8.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on February, 28. They expect $-1.27 EPS, up 30.60% or $0.56 from last year’s $-1.83 per share. After $-1.24 actual EPS reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 2.42% negative EPS growth.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>